Regencell Bioscience Holdings Ltd SEC filings RGC

Regencell Bioscience Holdings Ltd has 85 filings in SEC EDGAR's recent list, going back to Nov 13, 2020. Its latest annual report, Form 20-F, was filed on Oct 7, 2026 for the period ended Jun 30, 2026. The most recent current report (Form 6-K) was filed on May 22, 2026.

Regencell Bioscience Holdings Ltd SEC filings
Form Description Filed Period
424B5 Prospectus supplement May 19, 2026 —
424B5 Prospectus supplement Mar 30, 2026 —
F-3ASR Registration statement Mar 30, 2026 —
424B4 Prospectus Jul 20, 2021 —
FWP Free writing prospectus Jul 8, 2021 —
FWP Free writing prospectus Jun 30, 2021 —
F-1/A Amendment no. 3 to form f-1 Jun 23, 2021 —
F-1/A Amendment no. 2 to form f-1 Jun 11, 2021 —
F-1/A Amendment no. 1 to form f-1 Apr 26, 2021 —
F-1 Registration statement (foreign issuer) Mar 22, 2021 —

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
RGC (Nasdaq)
Incorporated in
Cayman Islands
Headquarters
Hong Kong
SEC filer status
Large accelerated filer
SEC CIK
1829667

Other Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.